| Outcomes of parenteral nutrition in patients with advanced cancer and malignant bowel obstruction |
| Design |
Retrospective, single-center cohort study
N= 68
|
| Objective |
To review individual patient outcomes on parenteral nutrition in the setting of advanced cancer with a diagnosis of malignant bowel obstruction and identify clinical and laboratory markers predictive of short- and long-term survival |
| Study Groups |
All patients (n= 68) |
| Inclusion Criteria |
Patients 18 years or older with a diagnosis of advanced cancer and an admission for malignant bowel obstruction between 1/1/2013 and 4/1/2021, discharged on parenteral nutrition |
| Exclusion Criteria |
Age <18, admissions for alternative diagnoses not for MBO, admissions requiring only perioperative PN, discharge without PN, receiving care at another institution resulting in untraceable clinical data |
| Methods |
Retrospective review of patients receiving PN for inoperable MBO. Data collected included cancer characteristics, PN characteristics, ECOG performance status, prior admissions, readmissions, hospice enrollment, and laboratory values. Complications of MBO and PN utilization were also recorded.
|
| Duration |
January 2013 to April 2021 |
| Outcome Measures |
Primary: Patient survival on PN
Secondary: PN-related complications, number of hospital readmissions following PN initiation
|
| Baseline Characteristics |
|
All patients (n= 68) |
| Age, years, median (IQR) |
57.5 (50.3–66) |
| Male sex, n (%) |
30 (44.1%) |
| White race, n (%) |
42 (63.6%) |
| Weight at PN initiation, kg, median (IQR) |
66 (55.8–76.3) |
| Six-month weight loss before PN initiation, %, median (IQR) |
8.4 (4.1–17.6) |
| Body mass index, median (IQR) |
22.6 (20–26.2) |
| Cancer features - Colorectal, n (%) |
15 (22.1%) |
| Cancer features - Gastric/gastroesophageal, n (%) |
8 (11.8%) |
| Cancer features - Gynecologic, n (%) |
7 (10.3%) |
| Cancer features - Appendiceal, n (%) |
24 (35.3%) |
| Cancer features - Other, n (%) |
14 (20.6%) |
| ECOG, n (%) - 0 |
6 (9.2%) |
| ECOG, n (%) - 1 |
29 (44.6%) |
| ECOG, n (%) - 2 |
16 (24.6%) |
| ECOG, n (%) - 3 |
14 (21.5%) |
| ECOG, n (%) - 4 |
1 (1.5%) |
| Laboratory values at PN initiation - Hemoglobin, g/dL, median (IQR) |
9.8 (8.8–11.7) |
| Laboratory values at PN initiation - WBC, cells/103uL, median (IQR) |
7.8 (5.2–10.8) |
| Laboratory values at PN initiation - Albumin, g/dL, median (IQR) |
3.1 (2.8–3.5) |
| Laboratory values at PN initiation - CRP, mg/dL, median (IQR) |
32 (9–76) |
| Nutrition Risk Index, median (IQR) |
80.8 (73.3–85.4) |
| Treatment features - History of exposure to chemotherapy, n (%) |
68 (100%) |
| Treatment features - Prior history of radiation therapy, n (%) |
3 (4.4%) |
| Treatment features - Prior surgical resection, n (%) |
45 (66.2%) |
| Treatment features - History of HIPEC, n (%) |
17 (25%) |
| Treatment features - Chemotherapy administered after MBO, n (%) |
43 (66.2%) |
| Results |
|
All patients (n= 68) |
| Median survival, days (IQR) |
142 (63.3–239.5) |
| Median number of hospital readmissions (range) |
2 (0–10) |
| Median days spent in hospital after starting PN (range) |
29 (0–105) |
| Patients with CRBSI, n (%) |
18 (26.5%) |
| Appendiceal cancer as predictive marker of improved survival (HR, 95% CI, p-value) |
0.53, 0.29–0.92, 0.023 |
| Adverse Events |
Catheter-related bloodstream infection (CRBSI) occurred in 26.5% of patients. Other complications included abdominal pain (75%), sepsis (36.8%), deep vein thrombosis (17.6%), ascites (33.8%), and pleural effusion (32.4%) |
| Study Author Conclusions |
The use of parenteral nutrition in end-of-life cancer care requires improvement. Recognizing patient outcomes and experiences with PN is essential for physicians and patients.
|
| Critique |
The study provides valuable insights into the outcomes of PN in advanced cancer patients with MBO, highlighting appendiceal cancer as a predictor of improved survival. However, the retrospective design and single-center setting may limit the generalizability of the findings. The study's reliance on medical records could introduce biases, and the sample size may not capture the full spectrum of PN outcomes across diverse cancer subtypes. Further prospective studies are needed to validate these findings and explore the broader applicability of PN in this patient population.
|